ASCO Guidelines cover art

All Episodes

ASCO Guidelines — 202 episodes

#
Title
1

Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update

2

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0

3

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.2

4

Treatment of Multiple Myeloma: ASCO Living Guideline Update 2026.1.1

5

Circulating Tumor DNA Testing in Solid Tumors and Lymphoma Guideline

6

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2

7

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 1

8

Systemic Treatment of Thyroid Cancer Guideline

9

Patient-Clinician Communication Guideline Update

10

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update

11

White Blood Cell Growth Factors Guideline Update

12

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2

13

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1

14

Systemic Therapy in Patients With mCRPC: ASCO Living Guideline 2026.1

15

Treatment of Multiple Myeloma: ASCO-OH (CCO) Living Guideline

16

Management of Cancer During Pregnancy Guideline

17

Management of Antineoplastic Extravasation: ONS-ASCO Guideline

18

Postmastectomy Radiation Therapy: ASTRO-ASCO-SSO Guideline

19

Geriatric Assessment Global Guideline

20

Oncology Medical Homes: ASCO-COA Standards Update

21

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2025.1 Part 2

22

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2025.1 Part 1

23

Medically Integrated Dispensing Pharmacy: ASCO-NCODA Standards Update

24

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Guideline

25

Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Guideline Update

26

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Rapid Update

27

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Guideline Update

28

Fertility Preservation in People with Cancer Guideline Update

29

Opioid Conversion in Adults with Cancer: MASCC-ASCO-AAHPM-HPNA-NICSO Guideline

30

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2024.3 Part 1

31

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.3 Part 2

32

TORS in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma Guideline

33

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline Update

34

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer Guideline

35

Treatment of Pleural Mesothelioma Update

36

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma Guideline

37

Systemic Therapy for SCLC Rapid Update

38

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.2

39

Management of Locally Advanced Rectal Cancer Guideline

40

Management of Stage III NSCLC Rapid Update

41

Selection of Germline Genetic Testing Panels in Patients with Cancer Guideline

42

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1

43

Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards

44

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer – CDK4/6 Inhibitors Rapid Update

45

Management of Fatigue in Adult Survivors of Cancer: ASCO-SIO Guideline Update

46

Palliative Care for Patients with Cancer Guideline Update

47

Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASCO Guideline

48

Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations

49

Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline Update

50

Vaccination of Adults with Cancer Guideline

51

Cannabis and Cannabinoids in Adults with Cancer Guideline

52

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update

53

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.3 Part 2

54

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.3 Part 1

55

Systemic Treatment of Patients with Metastatic Breast Cancer Resource-Stratified Guideline

56

Germline Testing in Patients with Breast Cancer: ASCO-SSO Guideline

57

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation Update

58

Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline

59

Management of Metastatic Renal Clear Cell Cancer Rapid Recommendation Update

60

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated GEP-NETs Guideline

61

Systemic Therapy for Melanoma Guideline Update

62

Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline

63

Management of Stage III NSCLC Rapid Recommendation Update

64

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy Guideline Update

65

Cancer Cachexia Rapid Recommendation Update

66

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.2

67

HER2 Testing in Breast Cancer: ASCO-CAP Guideline Update

68

Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Rapid Recommendation Update

69

VTE Prophylaxis and Treatment in Patients with Cancer Guideline Update

70

Management of Anxiety and Depression in Adult Survivors of Cancer Guideline Update

71

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.1 Part 2

72

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.1 Part 1

73

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer Guideline Update

74

Penile Cancer: EAU-ASCO Guideline

75

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update

76

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline

77

Targeted Therapy and Immunotherapy for Gastroesophageal Cancer Guideline

78

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2022.2 Part 2

79

Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2022.2 Part 1

80

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers Guideline

81

Use of Opioids for Adults with Pain from Cancer or Cancer Treatment Guideline

82

Treatment of Metastatic Colorectal Cancer Guideline

83

PARP Inhibitors in the Management of Ovarian Cancer Rapid Recommendation Update

84

Secondary Prevention of Cervical Cancer Resource-Stratified Guideline Update

85

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation Update

86

Integrative Medicine for Pain Management in Oncology: SIO-ASCO Guideline

87

Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update

88

Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline (Part 2)

89

Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations: ASCO Living Guideline (Part 1)

90

Biomarkers for Systemic Therapy in Metastatic Breast Cancer Guideline Update

91

Management of Metastatic Clear Cell Renal Cell Carcinoma Guideline

92

Systemic Therapy for Melanoma Rapid Recommendation Update

93

Management of Advanced HER2-Positive Breast Cancer and Brain Metastases Guideline Update

94

Systemic Therapy for Advanced HER2-Positive Breast Cancer Guideline Update

95

Exercise, Diet, and Weight Management During Cancer Treatment Guideline

96

Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline

97

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guideline Update

98

Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Triple Negative Breast Cancer Rapid Recommendation Update

99

Management and Care of Patients with Invasive Cervical Cancer: Resource-Stratified Guideline Rapid Recommendation Update

100

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

101

Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer Provisional Clinical Opinion

102

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected NSCLC Guideline Rapid Recommendation Update

103

Management of Stage III NSCLC Guideline

104

Adjuvant Therapy for Stage II Colon Cancer Guideline Update

105

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

106

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

107

Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

108

Considerations for the Use of Steroids: Management of irAEs Guideline (Part 13)

109

Ocular Toxicities: Management of irAEs Guideline (Part 12)

110

Cardiovascular Toxicities: Management of irAEs Guideline (Part 11)

111

Hematologic Toxicities: Management of irAEs Guideline (Part 10)

112

Nervous System Toxicities: Management of irAEs Guideline (Part 9)

113

Renal Toxicities: Management of irAEs Guideline (Part 8)

114

Musculoskeletal Toxicities: Management of irAEs Guideline (Part 7)

115

Endocrine Toxicities: Management of irAEs Guideline (Part 6)

116

Lung Toxicities: Management of irAEs Guideline (Part 5)

117

Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)

118

Cutaneous Toxicities: Management of irAEs Guideline (Part 3)

119

ICPi Overview: Management of irAEs Guideline (Part 1)

120

CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)

121

Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update

122

Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

123

Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Guideline Update

124

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Guideline Update

125

Telehealth in Oncology: Standards and Practice Recommendations

126

Salivary Gland Hypofunction and/or Xerostomia Induced by Non-Surgical Cancer Therapies: ISOO/MASCC/ASCO Guideline

127

Management of the Axilla in Early-Stage Breast Cancer: OH (CCO) and ASCO Guideline

128

Oncology Medical Home: ASCO and COA Standards

129

Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer Resource Stratified Guideline

130

Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer Guideline Update

131

Management of Salivary Gland Malignancy Guideline

132

Management of Dyspnea in Advanced Cancer Guideline

133

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Guideline Update

134

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline

135

Radiation Therapy for Small Cell Lung Cancer Guideline Endorsement

136

Initial Management of Non-Castrate Advanced, Recurrent, or Metastatic Prostate Cancer Guideline Update

137

PREVIEW: ASCO in Action CEO & CMO Interview

138

Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II to IVA Nasopharyngeal Carcinoma: CSCO-ASCO Guideline

139

Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline

140

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Update

141

Treatment of Metastatic Carcinoma and Myeloma of the Femur: Joint MSTS/ASTRO/ASCO Guideline

142

PARP Inhibitors in the Management of Ovarian Cancer Guideline

143

Metastatic Pancreatic Cancer Guideline Update

144

Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy Provisional Clinical Opinion Update

145

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers Guideline Update

146

Antiemetics Guideline Update

147

Treatment of Locally Advanced Esophageal Carcinoma Guideline

148

Management of Cancer Cachexia Guideline

149

Lung Cancer Surveillance After Definitive Curative-Intent Therapy Guideline

150

Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Guideline

151

Management of Hereditary Breast Cancer Guideline

152

Systemic Therapy for Melanoma Guideline

153

Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline

154

Management of Male Breast Cancer Guideline

155

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations Guideline

156

Bone Health and Bone-Targeted Therapies for Prostate Cancer Guideline Endorsement

157

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer Guideline

158

Optimum Imaging Strategies for Advanced Prostate Cancer Guideline

159

Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update

160

Molecular Biomarkers in Localized Prostate Cancer Guideline

161

Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards

162

Management of Osteoporosis in Survivors of Adult Cancers with Nonmetastatic Disease Guideline

163

Use of Endocrine Therapy for Breast Cancer Risk Reduction Guideline

164

Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer Guideline Update

165

Medication-Related Osteonecrosis of the Jaw Guideline

166

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Update

167

Potentially Curable Pancreatic Adenocarcinoma Guideline Update

168

Use of Biomarkers to Guide Decisions on Adjuvant Therapy for Early-Stage Invasive Breast Cancer Guideline Update

169

Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer PCO

170

Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer Guideline

171

Management of Cancer-associated Anemia with Erythropoiesis-Stimulating Agents Guideline

172

Treatment of Multiple Myeloma Guideline

173

Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors Endorsement

174

Adjuvant Therapy for Resected Biliary Tract Cancer Guideline

175

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Guideline

176

Early Detection for Colorectal Cancer Resource-Stratified Guideline

177

Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline

178

Safe Handling of Hazardous Drugs: ASCO Standards

179

Initial Diagnostic Workup of Acute Leukemia Guideline

180

Evaluating Susceptibility to Pancreatic Cancer PCO

181

Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cancer Guideline

182

Hypofractionated Radiation Therapy for Localized Prostate Cancer Guideline

183

Human Papillomavirus Testing in Head and Neck Carcinomas Endorsement Guideline

184

Clinically Localized Prostate Cancer Endorsement Guideline

185

Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression Guideline

186

Disease Management for Patients With Advanced HER2 Positive Breast Cancer and Brain Metastases Guideline

187

Systemic Therapy for Patients with Advanced HER2 Positive Breast Cancer Guideline

188

Integrative Therapies During and After Breast Cancer Treatment Guideline

189

Treatment of Malignant Pleural Mesothelioma Guideline

190

HER2 Testing in Breast Cancer Guideline

191

Metastatic Pancreatic Cancer Guideline

192

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline

193

Practical Assessment and Management of Vulnerabilities in Older Patients Guideline

194

ASCO Clinical Practice Guidelines Committee Leadership

195

Palliative Care in the Global Setting Guideline

196

Antiemetics Guideline

197

Patient-Clinician Communication Consensus Guideline

198

Integration of Palliative Care into Oncology Guideline

199

Fertility Preservation in Patients with Cancer Guideline

200

Optimizing Anticancer Therapy in Prostate Cancer Guideline

201

Outpatient Management of Fever and Neutropenia Guideline

202

Management of Immune-Related Adverse Events Guideline